BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 31302905)

  • 1. [Characterization of mutational pattern of patients with core-binding factor acute myeloid leukemia].
    He J; Chao H; Zhou M; Lu X; Chen T; Yang J; Jiang N; Zhang R
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2019 Jul; 36(7):657-661. PubMed ID: 31302905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of Genomic Landscape in Patients with Acute Myeloid Leukemia].
    Wang SM; Zheng HJ; Tian Y; Zhang JM; Yao JH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun; 28(3):797-801. PubMed ID: 32552938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive Mutation Profile in Acute Myeloid Leukemia Patients with
    Qin W; Chen X; Shen HJ; Wang Z; Cai X; Jiang N; Hua H
    Turk J Haematol; 2022 Jun; 39(2):84-93. PubMed ID: 35445594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Analysis of tyrosine kinases gene mutations in core binding factor related acute myeloid leukemia and its clinical significance].
    Qiao M; Li WY; Sun AN; Chen SN; Liang JY; Ding ZX; Feng YF; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):679-83. PubMed ID: 22339826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China.
    Gou H; Zhou J; Ye Y; Hu X; Shang M; Zhang J; Zhao Z; Peng W; Zhou Y; Zhou Y; Song X; Lu X; Ying B
    Tumour Biol; 2016 Jun; 37(6):7357-70. PubMed ID: 26676635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational landscape of patients with acute myeloid leukemia or myelodysplastic syndromes in the context of RUNX1 mutation.
    Wang K; Zhou F; Cai X; Chao H; Zhang R; Chen S
    Hematology; 2020 Dec; 25(1):211-218. PubMed ID: 32476595
    [No Abstract]   [Full Text] [Related]  

  • 7. [Clinical characteristics of newly diagnosed acute myeloid leukemia patients with NPM1 mutation].
    Wei H; Zhang YQ; Lin D; Wang Y; Zhou CL; Liu BC; Li W; Rao Q; Wang M; Mi YC; Wang JX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):11-5. PubMed ID: 24598642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population.
    Park SH; Lee HJ; Kim IS; Kang JE; Lee EY; Kim HJ; Kim YK; Won JH; Bang SM; Kim H; Song MK; Chung JS; Shin HJ
    Ann Lab Med; 2015 May; 35(3):288-97. PubMed ID: 25932436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TET2 gene mutation is unfavorable prognostic factor in cytogenetically normal acute myeloid leukemia patients with NPM1+ and FLT3-ITD - mutations.
    Tian X; Xu Y; Yin J; Tian H; Chen S; Wu D; Sun A
    Int J Hematol; 2014 Jul; 100(1):96-104. PubMed ID: 24859829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profiling of somatic mutations and fusion genes in acute myeloid leukemia patients with FLT3-ITD or FLT3-TKD mutation at diagnosis reveals distinct evolutionary patterns.
    Guan W; Zhou L; Li Y; Yang E; Liu Y; Lv N; Fu L; Ding Y; Wang N; Fang N; Liu Q; Wang B; Li F; Zhang J; Wang M; Wang L; Jing Y; Li Y; Yu L
    Exp Hematol Oncol; 2021 Apr; 10(1):27. PubMed ID: 33836835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
    Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M
    Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation.
    Ahn JS; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):61-70. PubMed ID: 26234722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations.
    Kumar D; Mehta A; Panigrahi MK; Nath S; Saikia KK
    Hematol Oncol Stem Cell Ther; 2018 Jun; 11(2):82-89. PubMed ID: 29079128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutation profile and associated clinical features in Chinese patients with cytogenetically normal acute myeloid leukemia.
    Wang S; Zhang YX; Huang T; Sui JN; Lu J; Chen XJ; Wang KK; Xi XD; Li JM; Huang JY; Chen B
    Int J Lab Hematol; 2018 Aug; 40(4):408-418. PubMed ID: 29573577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive mutational profiling of core binding factor acute myeloid leukemia.
    Duployez N; Marceau-Renaut A; Boissel N; Petit A; Bucci M; Geffroy S; Lapillonne H; Renneville A; Ragu C; Figeac M; Celli-Lebras K; Lacombe C; Micol JB; Abdel-Wahab O; Cornillet P; Ifrah N; Dombret H; Leverger G; Jourdan E; Preudhomme C
    Blood; 2016 May; 127(20):2451-9. PubMed ID: 26980726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome.
    Marková J; Marková J; Trnková Z; Michková P; Maaloufová J; Starý J; Cetkovský P; Schwarz J
    Leuk Lymphoma; 2009 Sep; 50(9):1448-60. PubMed ID: 19603346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Molecular Genetic Characteristics of Acute Myeloid Leukemia Patients with
    Jiang Y; Chao HY; Lu XZ; Wu P; Sun XC
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1661-1667. PubMed ID: 36476886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
    Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
    N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.
    Strickland SA; Shaver AC; Byrne M; Daber RD; Ferrell PB; Head DR; Mohan SR; Mosse CA; Moyo TK; Stricker TP; Vnencak-Jones C; Savona MR; Seegmiller AC
    Leuk Res; 2018 Feb; 65():67-73. PubMed ID: 29310020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational profiling of acute myeloid leukemia with normal cytogenetics in Brazilian patients: the value of next-generation sequencing for genomic classification.
    de Noronha TR; Mitne-Neto M; Chauffaille ML
    J Investig Med; 2017 Dec; 65(8):1155-1158. PubMed ID: 28923882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.